Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8121647 ...

TABLE OF CONTENTS | | | Page | | --- | --- | --- | | PART I | | | | Item 1. | Business | 7 | | Item 1A.Risk Factors | | 37 | | Item 1B. Unresolved Staff Comments | | 76 | | Item 2. | Properties | 76 | | Item 3. | Legal Proceedings | 76 | | Item 4. | Mine Safety Disclosures | 76 | | PART II | | | | Item 5. | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer | | | Purchases of Equity Securities | | 78 | | Item 6. | Reserved | 78 | | Management's Discussion and Analysis of Financial ...

Rapid Micro Biosystems MARCH 2022 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the "Company") solely for informational purposes. This presentation contains forward-looking statements. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements relating to the our full year 2022 commercial revenue outlook range and expected future revenue and growth; accelerati ...

Rapid Micro Biosystems MARCH 2022 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the "Company") solely for informational purposes. This presentation contains forward-looking statements. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements relating to the our full year 2022 commercial revenue outlook range and expected future revenue and growth; accelerati ...

Rapid Micro Biosystems Inc. (NASDAQ:RPID) Q4 2021 Earnings Conference Call March 4, 2022 8:30 AM ET Company Participants Mike Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Rob Spignesi - President and Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Casey Woodring - JPMorgan Dan Arias - Stifel Tejas Savant - Morgan Stanley Disclaimer*: This transcript is designed to be used alongside the freely available audio re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-812 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8121647 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1001 Pawtucket Boulevard West, Suite ...